← FDA DRUG APPROVALS

FDA ANDA · ANDA211318

AZITHROMYCIN

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA211318
TYPE
ANDA
ORIGINAL APPROVAL
2021-03-17
LATEST ACTION
2024-12-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

AZITHROMYCINDiscontinued
AZITHROMYCIN EQ 500MG BASE · TABLET · ORAL

Approval history

2024-12-23Manufacturing (CMC) · Supplement 2 · unknownAP
2021-03-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →